<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99106">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01863758</url>
  </required_header>
  <id_info>
    <org_study_id>GENA-21</org_study_id>
    <nct_id>NCT01863758</nct_id>
  </id_info>
  <brief_title>Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A</brief_title>
  <official_title>Prospective, Open-label, Multicenter Phase 3b Study to Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <authority>Germany: Paul Ehrlich Institute</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Poland: Office for Registration of medicinal products</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Spain:Spanish Agency for Medicine and Health products</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the number of breakthrough bleeds under tailored prophylaxis with human cell line
      recombinant factor FVIII (Human-cl rhFVIII) with the historical bleeding rate from patients
      who received Human-cl rhFVIII as on demand treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Reduction of total bleeding rate</measure>
    <time_frame>7-9 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction of the annualized total bleeding rate observed in the GENA-01 study (58.1 total bleeding episodes per patient per year) by 50% during individually tailored prophylaxis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of spontaneous bleeding rate</measure>
    <time_frame>7-9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction of the annualized spontaneous bleeding rate observed in the GENA-01 study (38.5 spontaneous bleeding episodes per patient per year) by 50% during individually tailored prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of bleeding rate</measure>
    <time_frame>7-9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction of annualized bleeding rate observed in the GENA-01 study by 50% in patients with 2x/week prophylaxis or less</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess thrombin generation assay in terms of usefulness in individualized therapy</measure>
    <time_frame>7-9 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Severe Haemophilia A</condition>
  <arm_group>
    <arm_group_label>Human-cl rhFVIII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human-cl rhFVIII</intervention_name>
    <arm_group_label>Human-cl rhFVIII</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe Haemophilia A (FVIII:C &lt;1%) according to medical history

          -  Male patients &gt;= 18 year Previous treatment with a FVIII concentrate (regular
             prophylaxis with good compliance or on-demand treatment) for at least 150 Exposure
             Days (EDs)

          -  Good documentation regarding dosing and bleeding frequency in the 6 months preceding
             study start

          -  Immunocompetence (CD4+ count &gt; 200/microliter)

          -  HIV-negative, if positive, viral load &lt;200 particles/microliter or &lt; 400,000
             copies/mL

        Exclusion Criteria:

          -  Any coagulation disorder other than Haemophilia A

          -  Present or past FVIII inhibitor activity (&gt; 0.6 BU)

          -  Severe liver or kidney disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sigurd Knaub, PhD</last_name>
    <phone>+41 5541512141</phone>
    <email>sigurd.knaub@octapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hungarian National Healthcare Center</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Medical and Health Science Center</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanador SRL</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Louis Turcanu Emergency Clinical Children's Hospital</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Thomas Hosptial</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>May 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
